Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody.

ABSTRACT:

Background

Ideally, monoclonal antibodies provide selective treatment by targeting the tumour, without affecting normal tissues. Therefore, antibody imaging is of interest, preferably in early stages of drug development. However, the imaging signal consists of specific, as well as non-specific, uptake. The aim of this study was to assess specific, target-mediated uptake in normal tissues, with immuno-PET in a phase I dose escalation study, using the anti-CD44 antibody RG7356 as example.

Results

Data from thirteen patients with CD44-expressing solid tumours included in an imaging sub-study of a phase I dose escalation clinical trial using the anti-CD44 antibody RG7356 was analysed. ⁸⁹Zirconium-labelled RG7356 (1 mg; 37 MBq) was administered after a variable dose of

SUBMITTER: Jauw YWS 

PROVIDER: S-EPMC5778091 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature